Recently, trametinib was approved for non-small cell lung carcinoma (NSCLC) harboring BRAF mutation, which implies that MEK inhibitors could be applied to other cancers with activation of the MAPK pathway. This evidence concerns the gene BRAF and non-small cell lung carcinoma.